Drug Trial Radar · NCT05958875
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
418
Planned (sponsor's estimate)
Start
Aug 1, 2024
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Dr. Inge WinterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Universität Münster
- First posted
- Jul 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Schizophrenia (SZ) affects approximately 4.5 million people across the European Union (EU) and is associated with annual healthcare and societal costs of 29 billion Euros. The impact on the daily life of patients is huge, ranging from frequent relapses and hospitalisations, the inability to maintain a job or continue scholing, to a low quality of life, impaired cognitive functioning, suicidal ideation and an increase morbidity rate, next to the large burden for carers 1. When diagnosed with schizophrenia or related disorder, patients are commonly prescribed antipsychotics. One-third of the schizophrenia patients are regarded treatment-resistant (TR), meaning that at least two antipsychotic trials have failed. Typically, clozapine is prescribed for TR patients, which is effective for approximately 40% of patients. Clozapine is among the most effective treatments, with the lowest all-cause mortality. Although it is among the most effective antipsychotics, it is generally not used earlier in the illness course due to a small risk of severe neutropenia/agranulocytosis, which is why patients treated with clozapine are intensely monitored. However, this small risk outweighs the burden of not receiving an effective treatment. Since clozapine is among the most effective treatments, this leads to the research question whether earlier initiation of third-line treatment ('early intensified' pharmacological treatment; EIPT) would be more beneficial than the current second-line treatments (treatment as usual; TAU). If this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments, hospitalisations, and recommendations for adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs The INTENSIFY-Schizophrenia trial is part of the larger Horizon 2021 project Psych-STRATA, with the central goal of paving the way for a shift towards a treatment decision-making process tailored for the individual at risk for treatment resistance. To that end, the inestigators aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for treatment resistance across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression. The current protocol focuses on the sample of schizophrenia patients.
Conditions
- Schizophrenia and Related Disorders
- Early Treatment-Resistance
Interventions
ClozapineDrug
Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.
Second-line Antipsychotics (treatment as usual)Drug
Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in symptom severity on Positive and Negative Syndrome ScaleTime frame: 6 weeks
Locations
13 sites in 5 countries. Site status is shown where the registry gives one.
Medical University Innsbruck
Innsbruck, Austria · Recruiting
Bezirkskliniken Schwaben, Bezirkskrankenhaus Augsburg
Augsburg, Germany · Not yet recruiting
Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld
Bielefeld, Germany · Recruiting
LWL-Klinik Dortmund, Bereich Forschung & Wissenschaft
Dortmund, Germany · Recruiting
University Hospital Frankfurt am Main - Goethe University
Frankfurt am Main, Germany · Recruiting
Klinik für Psychiatrie und Psychotherapie der Universitätsmedizin Mainz
Mainz, Germany · Recruiting
Westfälische Wilhelms-Universität Münster
Münster, Germany · Recruiting
Universita degli Studi di Brescia
Brescia, Italy · Recruiting
University of Cagliari
Cagliari, Italy · Recruiting
Università degli studi della Campania Luigi Vanvitelli
Naples, Italy · Recruiting
Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino"
Turin, Italy · Recruiting
Fundació Clínic per a la Recerca Biomèdica
Barcelona, Spain · Recruiting
King's College London, Psychiatry & Cognitive Neuroscience
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.